Your SlideShare is downloading. ×
Research aarkstore enterprise mucositis partnering 2007 2012
Research aarkstore enterprise mucositis partnering 2007 2012
Research aarkstore enterprise mucositis partnering 2007 2012
Research aarkstore enterprise mucositis partnering 2007 2012
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Research aarkstore enterprise mucositis partnering 2007 2012

55

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
55
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. ResearchAarkstore Enterprise Mucositis Partnering 2007-2012The Mucositis Partnering 2007-2012 report provides understanding and access to the mucositispartnering deals and agreements entered into by the worlds leading healthcare companies.•Trends in mucositis partnering deals•Top mucositis deals by value•Deals listed by company A-Z, industry sector, stage of development, technology typeThe Mucositis Partnering 2007-2012 provides understanding and access to the mucositispartnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of mucositis partnering deals. The majority of deals arediscovery or development stage whereby the licensee obtains a right or an option right tolicense the licensors mucositis technology. These deals tend to be multicomponent, startingwith collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partner’s negotiated deals terms provides criticalinsight into the negotiation process in terms of what you can expect to achieve during thenegotiation of terms. Whilst many smaller companies will be seeking details of the paymentsclauses, the devil is in the detail in terms of how payments are triggered – contract documentsprovide this insight where press releases do not.This data driven report contains over 20 links to online copies of actual mucositis deals andcontract documents as submitted to the Securities Exchange Commission by companies andtheir partners, where available. Contract documents provide the answers to numerousquestions about a prospective partner’s flexibility on a wide range of important issues, many ofwhich will have a significant impact on each party’s ability to derive value from the deal.The initial chapters of this report provide an orientation of mucositis partnering trends.Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of thetrends in mucositis partnering since 2007, including a summary of deals by industry sector, stageof development, deal type, and technology type. Numerous tables provide outline financialtrends.
  • 2. Chapter 3 provides an overview of the leading mucositis deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. For more information please visit link: http://www.aarkstore.com/reports/Mucositis-Partnering-2007-2012-225584.html Neel Aarkstore Enterprise Phone:08149852585 Email:enquiry@aarkstore.com URL:www.aarkstore.com http://www.facebook.com/aarkstoreenterprise http://in.linkedin.com/in/aarkstoreBiomarker Partnering Terms & AgreementsCompanion Diagnostics Partnering Terms & AgreementsBioinformatics Partnering Terms & AgreementsPersonalized Medicine Partnering Terms and AgreementsPersonalized Medicine Partnering Terms and AgreementsDermatology Partnering Terms and AgreementsCardiovascular Partnering Terms and AgreementsObstretics Partnering 2007-2012Musculoskeletal Partnering AgreementsOncology Partnering Terms and AgreementsPediatrics Partnering Terms and AgreementsMetabolic Partnering Terms and AgreementsImmunology Partnering Terms and AgreementsGenitourinary Partnering Terms and Agreements
  • 3. Gastrointestinal Partnering Terms and AgreementsDental Partnering Terms and AgreementsCentral Nervous System Partnering Terms and AgreementsSexual Health Partnering Terms and AgreementsMucositis Partnering 2007-2012Oral Health Partnering 2007-2012AIDS Partnering 2007-2012Allergy Partnering 2007-2012Systemic Lupus Partnering 2007-2012Inflammatory Partnering 2007-2012Gynecology Partnering Terms and AgreementsRespiratory Partnering Terms and AgreementsBacterial Partnering Terms and AgreementsViral Partnering Terms and AgreementsAnthrax Partnering 2007-2012E.coli Partnering 2007-2012MRSA Partnering 2007-2012Sepsis Partnering 2007-2012Common Cold Partnering 2007-2012Hepatitis Partnering 2007-2012Herper simplex Partnering 2007-2012HIV Partnering 2007-2012Influenza Partnering 2007-2012RSV Partnering 2007-2012Parasitic Partnering 2007-2012Fungal Partnering 2007-2012Tropical Disease Partnering 2007-2012Dengue Fever Partnering 2007-2012Malaria Partnering 2007-2012Renal Failure Partnering 2007-2012Dialysis Partnering 2007-2012Genitourinary Symptoms Partnering 2007-2012Chronic Kidney Disease Partnering 2007-2012
  • 4. Blood Substitute Partnering 2007-2012Anemia Partnering 2007-2012Hemophilia Partnering 2007-2012

×